- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00560794
Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
Open-label, Multicenter Phase II Study to Investigate the Efficacy, Safety, and Tolerability of the Bispecific T-cell Engager (BiTE®) MT103 in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
Baden-Württemberg
-
Ulm, Baden-Württemberg, Alemanha, 89081
- Universitatsklinikum Ulm
-
-
Bayern
-
Würzburg, Bayern, Alemanha, 97080
- Julius-Maximilians-Universität Würzburg
-
-
Hessen
-
Frankfurt, Hessen, Alemanha, 60590
- Klinikum der J.W. Goethe Universität
-
-
Nordrhein-Westfalen
-
Münster, Nordrhein-Westfalen, Alemanha, 48129
- Universitatsklinikum Munster
-
-
Sachsen
-
Dresden, Sachsen, Alemanha, ´01307
- Universitätsklinikum Carl Gustav Carus
-
-
Schleswig-Holstein
-
Kiel, Schleswig-Holstein, Alemanha, 24116
- Universitätsklinikum Schleswig-Holstein im Städtischen Krankenhaus Kiel
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- B-precursor ALL patients in complete hematological remission with molecular failure or molecular relapse starting at any time after consolidation I of front-line therapy within German Multicenter Study Group on Adult Acute Lymphoblastic Leukemia (GMALL) standards or at any time outside GMALL standards.
- Patients must have a molecular marker for evaluation of minimal residual disease which is either Breakpoint cluster region/gene on human chromosome #9 (Bcr/abl) at any detection level or individual rearrangements of immunoglobulin or T-cell receptor (TCR)-genes measured by an assay with a sensitivity of minimum 10^-4: At least one individual marker at a quantitative level ≥ 10^-4.
- Eastern Cooperative Oncology Group (ECOG) Performance Status < 2
- Ability to understand and willingness to sign a written informed consent
- Signed and dated written informed consent is available
Exclusion Criteria:
- Current extra medullar involvement
- History of or current relevant central nervous system (CNS) pathology (except migraine/headache and/or previous infiltration of cerebrospinal fluid (CSF) by ALL)
- Current infiltration of cerebrospinal fluid by ALL
- History of or current autoimmune disease
- Autologous stem cell transplantation within 6 weeks prior to study entry
- Any prior allogeneic stem cell transplantation
- Cancer chemotherapy within 4 weeks prior to study treatment (except for intrathecal prophylaxis and/or low dose maintenance therapy such as vinca alkaloids, mercaptopurine, methotrexate, steroids)
- Radiotherapy within 4 weeks prior to study treatment
- Therapy with monoclonal antibodies (Rituximab, MabCampath) within 6 weeks prior to study treatment
- Known hypersensitivity to immunoglobulins or to any other component of the study drug formulation
- Presence of human anti-murine antibodies (HAMA)
- Abnormal bone marrow, renal or hepatic function
- Indication for a hypercoagulative state
- History of malignancy other than ALL within 5 years prior to study entry, with the exception of basal cell carcinoma of the skin or cervix carcinoma in situ
- Active severe infection, any other concurrent disease or medical condition that are deemed to interfere with the conduct of the study as judged by the investigator
- Known infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus (HbsAg positive) or hepatitis C virus (anti-HCV positive)
- Pregnant or nursing women
- Women of childbearing potential not willing to use an effective form of contraception during participation in the study and at least 3 months thereafter or male patients not willing to ensure effective contraception during participation in the study and at least three months thereafter
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Blinatumomab
Participants received blinatumomab as continuous intravenous infusion at constant flow rate over 4 weeks followed by a 2 week treatment-free period (defined as one treatment cycle), for up to a maximum of 10 cycles.
The initial dose was 15 μg/m^2/day.
A dose increase to 30 μg/m^2/day was permitted with evidence for insufficient response to blinatumomab treatment.
|
Administered by continuous intravenous (CIV) over 4 weeks per cycle
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Percentage of Participants With a Minimal Residual Disease (MRD) Response Within 4 Cycles of Treatment
Prazo: Within 4 treatment cycles, 24 weeks
|
MRD Response is defined as:
|
Within 4 treatment cycles, 24 weeks
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Percentage of Participants With an MRD Response After Each Treatment Cycle
Prazo: At the end of each treatment cycle - Weeks 4, 10, 16, and 22.
|
MRD Response is defined as:
|
At the end of each treatment cycle - Weeks 4, 10, 16, and 22.
|
Time to Hematological Relapse
Prazo: Up to the data cut-off date of 14 January 2010; maximum duration of follow-up was 564 days.
|
The time to hematological relapse is defined as the time between start of first infusion of blinatumomab and the first result of hematological relapse. Participants without an event of hematological relapse were censored on their last available date of bone marrow aspiration/biopsy. Hematological relapse is defined as > 5% leukemia cells in bone marrow. Time to hematological relapse was analyzed using Kaplan-Meier methods. |
Up to the data cut-off date of 14 January 2010; maximum duration of follow-up was 564 days.
|
Time to MRD Progression
Prazo: Up to the data cut-off date of 14 January 2010; Median follow-up time was 155 days
|
Time to MRD progression is defined for participants who do not show MRD response at any time during the study as the time from start of first infusion until the first result of MRD progression or hematological relapse, if no MRD progression was diagnosed before hematological relapse. For participants who showed MRD response during the study the time to MRD progression is defined as the time from the date of the first MRD response to the date of MRD relapse. Participants without an event of MRD progression were censored on the day of their last bone marrow aspiration/biopsy. Participants who received a bone marrow transplant were censored on the last day of bone marrow aspiration/biopsy before transplantation. MRD progression is defined as the increase in the MRD level by 1 log as compared to the baseline level (equal to a 10-fold increase in the number of MRD cells), and had to be confirmed within 6 weeks. |
Up to the data cut-off date of 14 January 2010; Median follow-up time was 155 days
|
Time to MRD Relapse
Prazo: Up to the data cut-off date of 14 January 2010; Median follow-up time was 116.5 days
|
Time to MRD relapse is defined only for participants with an MRD response during the study, defined as the time between the date of the first MRD response and the date of MRD relapse. If a participant experienced hematological relapse without having shown MRD positivity before then the time point of MRD relapse is defined as the time point of hematological relapse. Participants without an event of MRD relapse or hematological relapse were censored on the day of their last available bone marrow aspiration/biopsy. If a participant received a bone marrow transplant the last day of bone marrow aspiration/biopsy before transplantation was used as time point for censoring. MRD relapse is defined as reappearance of bcr/abl, and/or t(4;11) translocation at any detection level, and/or by individual rearrangements of immunoglobulin or T-cell receptor genes ≥10^-4 for at least 1 individual marker measured by an assay with a sensitivity of minimum 10^-4 and should be confirmed within 6 weeks. |
Up to the data cut-off date of 14 January 2010; Median follow-up time was 116.5 days
|
Number of Participants With Adverse Events
Prazo: From the start of study treatment until up to 4 weeks after the end of study treatment. The median treatment duration was 87.3 days.
|
The severity (or intensity) of AEs was evaluated according to the grading scale provided in the Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events (CTCAE), version 3.0, or according to the following: Grade 1 - Mild AE; Grade 2 - Moderate AE; Grade 3 - Severe AE; Grade 4 - Life-threatening or disabling AE; Grade 5 - Death. The investigator used medical judgment to determine if there was a causal relationship (ie, related, unrelated) between an adverse event and blinatumomab. A serious adverse event (SAE) is any untoward medical occurrence or effect that, at any dose results in death, is life-threatening, requires or prolongs hospitalization, results in persistent or significant disability or incapacity, or is a congenital anomaly or birth defect. In addition, all laboratory abnormalities of grade four severity that occur during or after administration of the investigational drug, any overdose and a pregnancy or fathering were reported as SAEs. |
From the start of study treatment until up to 4 weeks after the end of study treatment. The median treatment duration was 87.3 days.
|
Change From Screening Value in B-cell Count During Cycle 1
Prazo: At Screening and in Cycle 1 at the start of infusion, 45 minutes, 2, 6, 12, 24 hours and at Days 2, 7, 14, 21, 28 and 35 after the start of infusion.
|
B-cells were measured by flow cytometry.
|
At Screening and in Cycle 1 at the start of infusion, 45 minutes, 2, 6, 12, 24 hours and at Days 2, 7, 14, 21, 28 and 35 after the start of infusion.
|
Change From Screening Value in T-cell Count During Cycle 1
Prazo: At Screening and in Cycle 1 at the start of infusion, 45 minutes, 2, 6, 12, 24 hours and at Days 2, 7, 14, 21, 28 and 35 after the start of infusion.
|
T-cells were measured by flow cytometry.
|
At Screening and in Cycle 1 at the start of infusion, 45 minutes, 2, 6, 12, 24 hours and at Days 2, 7, 14, 21, 28 and 35 after the start of infusion.
|
Serum Cytokine Peak Levels in Cycle 1
Prazo: Cycle 1 at pre-dose and at post infusion start at 45 minutes; 2, 6, 12, 24, and 48 hours; 7, 14, 21, and 28 days.
|
The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-4, IL-6, IL-8, IL-10, tumor necrosis factor (TNF)-α and interferon gamma (IFN)-γ using fluorescence-activated cell sorter (FACS)-based cytometric bead array (CBA) system.The limit of detection (LOD) for the cytokine determination was 20 pg/mL, the limit of quantification (LOQ) was 125 pg/mL.
|
Cycle 1 at pre-dose and at post infusion start at 45 minutes; 2, 6, 12, 24, and 48 hours; 7, 14, 21, and 28 days.
|
Serum Blinatumomab Concentration at Steady State
Prazo: Cycle 1 at predose and at 2, 6, and 12 hours after start of infusion then weekly until end of the cycle, and at 1, 2, 4, 6, 8, and 24 hours after stop of infusion.
|
The mean serum concentration of blinatumomab during cycle 1.
The LOQ of the assay was 100 pg/mL, and the limit of detection (LOD) was 3 pg/mL.
|
Cycle 1 at predose and at 2, 6, and 12 hours after start of infusion then weekly until end of the cycle, and at 1, 2, 4, 6, 8, and 24 hours after stop of infusion.
|
Area Under the Drug Concentration-time Curve From Time Zero to Infinity
Prazo: Cycle 1 at predose and at 2, 6, and 12 hours after start of infusion then weekly until end of the cycle, and at 1, 2, 4, 6, 8, and 24 hours after stop of infusion.
|
Cycle 1 at predose and at 2, 6, and 12 hours after start of infusion then weekly until end of the cycle, and at 1, 2, 4, 6, 8, and 24 hours after stop of infusion.
|
|
Apparent Volume of Distribution
Prazo: Cycle 1 at predose and at 2, 6, and 12 hours after start of infusion then weekly until end of the cycle, and at 1, 2, 4, 6, 8, and 24 hours after stop of infusion.
|
Cycle 1 at predose and at 2, 6, and 12 hours after start of infusion then weekly until end of the cycle, and at 1, 2, 4, 6, 8, and 24 hours after stop of infusion.
|
|
Clearance of Blinatumomab
Prazo: Cycle 1 at predose and at 2, 6, and 12 hours after start of infusion then weekly until end of the cycle, and at 1, 2, 4, 6, 8, and 24 hours after stop of infusion.
|
Cycle 1 at predose and at 2, 6, and 12 hours after start of infusion then weekly until end of the cycle, and at 1, 2, 4, 6, 8, and 24 hours after stop of infusion.
|
|
Terminal Half-life of Blinatumomab
Prazo: Cycle 1 at predose and at 2, 6, and 12 hours after start of infusion then weekly until end of the cycle, and at 1, 2, 4, 6, 8, and 24 hours after stop of infusion.
|
Cycle 1 at predose and at 2, 6, and 12 hours after start of infusion then weekly until end of the cycle, and at 1, 2, 4, 6, 8, and 24 hours after stop of infusion.
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Ralf Bargou, Professor, Julius-Maximilians-Universität Würzburg
Publicações e links úteis
Publicações Gerais
- Zhu M, Wu B, Brandl C, Johnson J, Wolf A, Chow A, Doshi S. Blinatumomab, a Bispecific T-cell Engager (BiTE((R))) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications. Clin Pharmacokinet. 2016 Oct;55(10):1271-1288. doi: 10.1007/s40262-016-0405-4.
- Zugmaier G, Topp MS, Alekar S, Viardot A, Horst HA, Neumann S, Stelljes M, Bargou RC, Goebeler M, Wessiepe D, Degenhard E, Gokbuget N, Klinger M. Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. Blood Cancer J. 2014 Sep 5;4(9):244. doi: 10.1038/bcj.2014.64. No abstract available.
- Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS, Gokbuget N, Neumann S, Goebeler M, Viardot A, Stelljes M, Bruggemann M, Hoelzer D, Degenhard E, Nagorsen D, Baeuerle PA, Wolf A, Kufer P. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood. 2012 Jun 28;119(26):6226-33. doi: 10.1182/blood-2012-01-400515. Epub 2012 May 16.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Processos Patológicos
- Doenças do sistema imunológico
- Neoplasias por Tipo Histológico
- Neoplasias
- Distúrbios Linfoproliferativos
- Doenças Linfáticas
- Distúrbios imunoproliferativos
- Processos Neoplásicos
- Leucemia
- Leucemia-Linfoma Linfoblástico de Células Precursoras
- Leucemia Linfóide
- Neoplasia Residual
- Efeitos Fisiológicos das Drogas
- Agentes Antineoplásicos
- Fatores imunológicos
- Blinatumomabe
- Anticorpos Biespecíficos
Outros números de identificação do estudo
- MT103-202
- 2006-006520-19 (Número EudraCT)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Blinatumomab (MT103)
-
Amgen Research (Munich) GmbHConcluídoLinfoma não-Hodgkin recidivanteAlemanha
-
Amgen Research (Munich) GmbHConcluído
-
Amgen Research (Munich) GmbHConcluídoLinfoma Difuso de Grandes Células BAlemanha
-
Amgen Research (Munich) GmbHConcluídoLeucemia linfoblástica agudaEstados Unidos, Alemanha, Áustria, Canadá, França, Itália, Holanda
-
Amgen Research (Munich) GmbHConcluídoLeucemia linfoblástica agudaEstados Unidos, Reino Unido, Alemanha, Espanha, França, Itália
-
Amgen Research (Munich) GmbHConcluídoLeucemia Linfoblástica Aguda de Células BÁustria, Bélgica, França, Alemanha, Itália, Holanda, Polônia, Romênia, Federação Russa, Espanha, Reino Unido
-
The First Affiliated Hospital of Soochow UniversityAinda não está recrutandoLeucemia Linfoblástica Aguda de Células BChina
-
AmgenConcluído
-
AmgenRescindidoLeucemia Linfoblástica Aguda Recidivante/Refratária Precursora BEstados Unidos, França, Itália, Bélgica, Canadá, México, Alemanha, Republica da Coréia, Reino Unido, Taiwan, Austrália, Espanha, Áustria, Israel, Tcheca, Grécia, Federação Russa, Polônia, Peru, Bulgária, Irlanda
-
National Cancer Institute (NCI)RecrutamentoLeucemia Linfoblástica Aguda Recorrente B | Leucemia Linfoblástica Aguda Refratária B | B Leucemia Linfoblástica Aguda, Cromossomo Filadélfia NegativoEstados Unidos